Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Tirzepatide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention. Browse Tirzepatide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 12:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
178
Shown on this page
12
Current sort
Recently updated
Therapy scope
Tirzepatide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Tirzepatide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 97–108 of 178 matching trials for Tirzepatide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Metabolic Surgery for Atrial Fibrillation Elimination

NCT07027969
View directory record Official record
Conditions
Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Interventions
Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
Procedure · Drug
Lead sponsor
Ali Aminian
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Recruiting Phase 2 Interventional

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

NCT06811324
View directory record Official record
Conditions
Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss
Interventions
Tirzepatide
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users

NCT06467604
View directory record Official record
Conditions
Obesity
Interventions
Surveys, Indirect Calorimetry, Body composition, Anthropometrics
Behavioral · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Completed Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

NCT06326060
View directory record Official record
Conditions
Obesity
Interventions
NNC0519-0130, Placebo, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
49
States / cities
Mesa, Arizona • Little Rock, Arkansas • Searcy, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Recruiting Early Phase 1 Interventional

A Study of a Weight Loss Intervention in People With Endometrial Cancer

NCT06751589
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Tirzepatide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Completed Phase 4 Interventional

A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)

NCT06605703
View directory record Official record
Conditions
Obesity, Overweight
Interventions
WW Clinic, Bupropion-Naltrexone, Bupropion-Naltrexone-Metformin
Behavioral · Drug
Lead sponsor
WW International Inc
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Recruiting Phase 4 Interventional

Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

NCT06774079
View directory record Official record
Conditions
Crohn Disease
Interventions
Tirzepatide, Mediterranean diet
Drug · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Not yet recruiting Phase 2 Interventional

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

NCT06732245
View directory record Official record
Conditions
Obesity and Overweight
Interventions
NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide
Drug
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
19 Years to 80 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Recruiting Phase 2 Interventional

Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

NCT05933499
View directory record Official record
Conditions
Obesity
Interventions
Bimagrumab, Tirzepatide, Calcium/Vitamin D, Lifestyle and nutrition counseling
Drug · Dietary Supplement · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Completed Phase 3 Interventional

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT06047548
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Pelham, Alabama • Los Angeles, California • Santa Ana, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Recruiting Phase 2 Interventional

Tirzepatide to Slow Biological Aging

NCT07220473
View directory record Official record
Conditions
Aging, LONGEVITY 1
Interventions
Zepbound
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

NCT06037252
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Concord, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 20, 2026, 12:22 AM EDT

About this Tirzepatide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Tirzepatide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Tirzepatide.